Using continuous glucose monitors for diabetes management after hospital discharge

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

This study is testing if using continuous glucose monitors can help adults with diabetes manage their blood sugar better after leaving the hospital.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Vanderbilt University Medical Center (other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Nashville, Tennessee)
• Trial ID: NCT06852950 on ClinicalTrials.gov

What this trial studies

This study focuses on enhancing diabetes management for patients transitioning from hospital to home by utilizing continuous glucose monitoring systems. It aims to increase patient awareness and satisfaction regarding blood glucose monitoring through the use of devices like the Libre 3 Plus and Dexcom G7. Eligible participants include adults with hyperglycemia requiring insulin therapy, who will be monitored for their glucose levels post-discharge. The study seeks to evaluate the effectiveness of these monitoring systems in improving patient outcomes.

Who should consider this trial

Good fit: Ideal candidates are non-pregnant adults aged 18 and older with hyperglycemia requiring insulin therapy during hospitalization.

Not a fit: Patients currently using continuous glucose monitoring systems or those with certain medical conditions, such as recent chemotherapy or planned major surgery, may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to better diabetes management and improved patient satisfaction for individuals transitioning from hospital care to home.

How similar studies have performed: Other studies have shown positive outcomes with continuous glucose monitoring in diabetes management, indicating that this approach is supported by existing evidence.

Eligibility criteria

Inclusion Criteria:

* Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
* Able to give informed consent
* Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
* POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
* Need glucose readings greater than or equal to one time per day
* Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone

Exclusion Criteria:

* Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
* Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
* Received chemotherapy during current hospitalization
* Planning on major surgery within 10-15 days
* Hemodialysis or peritoneal dialysis
* Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
* Vitamin C use of more than 500 milligrams per day
* Hydroxyurea use
* Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
* Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
* Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
* Skin allergy to adhesives

Where this trial is running

Nashville, Tennessee

• Vanderbilt University Medical Center — Nashville, Tennessee, United States (RECRUITING)

Study contacts

• Study coordinator: Angel Morvant, MD

Conditions: Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia